Short Interest in Singular Genomics Systems, Inc. (NASDAQ:OMIC) Drops By 18.9%

Singular Genomics Systems, Inc. (NASDAQ:OMIC) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 71,200 shares, a decrease of 18.9% from the October 15th total of 87,800 shares. Currently, 4.8% of the shares of the stock are sold short. Based on an average trading volume of 105,000 shares, the days-to-cover ratio is currently 0.7 days.

Singular Genomics Systems Price Performance

OMIC traded down $0.85 during trading on Friday, reaching $21.90. The stock had a trading volume of 29,598 shares, compared to its average volume of 34,549. The stock has a market cap of $55.01 million, a PE ratio of -0.62 and a beta of 1.51. The company has a debt-to-equity ratio of 0.04, a quick ratio of 8.04 and a current ratio of 7.37. Singular Genomics Systems has a one year low of $5.34 and a one year high of $23.41. The business has a 50-day moving average of $15.32 and a 200-day moving average of $11.33.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.74 million.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.